Citations

Clear

382 citation(s) found for "Shapiro, CL".

Preparing Regenerative Therapies for Clinical Application: Proposals for Responsible Translation
Smith, Cambray , Arthurs, Jennifer R. , Master, Zubin , Smith, Cambray G, Master, Zubin , Shapiro, Shane A.

Mayo Clinic

Regenerative Medicine | January 17, 2019 | Volume: 14 | Issue: 2 | Pages: 77-84

10.2217/rme-2018-0163 | PMID 30651044 Get It

Cutting Edge: HDAC3 Protects Double-Positive Thymocytes from P2X7 Receptor–Induced Cell Death
Philips, Rachael L. , McCue, Shaylene , Rajcula, Matthew, Shapiro, Virginia Smith , Shapiro, Virginia S

Mayo Clinic

The Journal of Immunology | January 9, 2019 | Volume: 202 | Issue: 4 | Pages: 1033-1038

10.4049/jimmunol.1801438 | PMID 30626694 Get It

Abstract Intricate life-versus-death decisions are programmed during T cell development, and the regulatory mechanisms that coordinate their activation and repression are still under investigation. In this study, HDAC3-deficient double-positive (DP) thymocytes exhibit a severe decrease in numbers. The thymic cortex is rich in ATP, which is released by macrophages that clear apoptotic DP thymocytes that fail to undergo positive selection. We demonstrate that HDAC3 is required to repress expression of the purinergic receptor P2X7 to prevent DP cell death. HDAC3-deficient DP thymocytes upregulate the P2X7 receptor, increasing sensitivity to ATP-induced cell death. P2rx7/HDAC3-double knockout mice show a partial rescue in DP cell number. HDAC3 directly binds to the P2rx7 enhancer, which is hyperacetylated in the absence of HDAC3. In addition, RORγt binds to the P2rx7 enhancer and promotes P2X7 receptor expression in the absence of HDAC3. Therefore, HDAC3 is a critical regulator of DP thymocyte survival and is required to suppress P2X7 receptor expression.
Tangential Flow Filtration for Highly Efficient Concentration of Extracellular Vesicles from Large Volumes of Fluid
Busatto, Sara , Vilanilam, George K. , Ticer, Taylor , Lin, Wen‐Lang, Shapiro, Shane A. , Bergese, Paolo , Wolfram, Joy , Vilanilam, George , Shapiro, Shane , Bergese, Paolo , Wolfram, Joy , Dickson, Dennis W.

Mayo Clinic

Cells | December 18, 2018 | Volume: 7 | Issue: 12 | Pages: 273

10.3390/cells7120273 | PMID 30558352 Get It

Concentration of extracellular vesicles (EVs) from biological fluids in a scalable and reproducible manner represents a major challenge. This study reports the use of tangential flow filtration (TFF) for the highly efficient isolation of EVs from large volumes of samples. When compared to ultracentrifugation (UC), which is the most widely used method to concentrate EVs, TFF is a more efficient, scalable, and gentler method. Comparative assessment of TFF and UC of conditioned cell culture media revealed that the former concentrates EVs of comparable physicochemical characteristics, but with higher yield, less single macromolecules and aggregates (<15 nm in size), and improved batch-to-batch consistency in half the processing time (1 h). The TFF protocol was then successfully implemented on fluids derived from patient lipoaspirate. EVs from adipose tissue are of high clinical relevance, as they are expected to mirror the regenerative properties of the parent cells.
Abstract P167: Altered Gut Microbiome Contributes to Metabolite Biomarkers in Patients With Pulmonary Hypertension
Kim, Seungbum , Walejko, Jacquelyn M., Jordan, Ray, Shapiro, Brian P. , Richards, Elaine M. , Raizada, Mohan K. , Rigatto, Katya , Pepine, Carl J.

Mayo Clinic

Hypertension | December 6, 2018 | Volume: 72 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.72.suppl_1.p167 Get It

Objectives: Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease without effective cure. The objective of this study is to test the hypothesis that PAH patients have a distinct gut microbiome composition acting as a driving force for the increased PAH metabolic biomarkers, acyl carnitines and urate. Methods: Fecal samples from 18 type 1 PAH patients (mean pulmonary arterial pressure [mPAP] 57.4±16.7 mmHg) and 13 reference subjects in Brazil were collected for comparison of microbiome using shotgun metagenomics. Plasma samples from 33 type I PAH patients (mPAP 51.7± 13.5 mmHg) and 19 reference subjects in the USA were used for untargeted metabolomic analysis. Results: More than 80 bacterial taxa were differentially enriched in the microbiomes of the PAH cohort. Random forest machine-learning algorithm predicted PAH patients with 82.4% accuracy from their gut microbiome composition. The most increased taxa in the PAH microbiome were trimethylamine (TMA) producing bacteria like Collinsella (P=0.0037). The PAH metabolome also showed increases of gut microbiome-derived short chain acyl carnitines like isubutyrylcarnitine (P=0.010) and valerylcarnitine (P=0.030), which are the precursors of TMA. In addition, increased urate (P=0.0004) and allantoin (P=0.027) in PAH plasma correlated with significantly increased enzymes producing urate in the PAH microbiome (purine metabolism (P=0.017) and xanthine oxidase (P<0.05)). Conclusion: These findings suggest that the random forest modeling of the gut microbiome composition can be used for prediction of PAH and that the unique gut microbiome of PAH influences acyl carnitines and urate metabolism to contribute to pathophysiology.
Faculty Opinions recommendation of CCR7 defines a precursor for murine iNKT cells in thymus and periphery.
Dash, Barsha, Shapiro, Virginia Smith

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 9, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.733808508.793551274 Get It

Emergency Physicians' Perceived Influence of EHR Use on Clinical Workflow and Performance Metrics
Denton, Courtney A., Soni, Hiral , Kannampallil, Thomas , Serrichio, Anna, Shapiro, Jason S. , Traub, Stephen J., Patel, Vimla Lodhia

Mayo Clinic

Applied Clinical Informatics | September 12, 2018 | Volume: 09 | Issue: 03 | Pages: 725-733

10.1055/s-0038-1668553 | PMID 30208497 Get It

Objective Over the last decade, electronic health records (EHRs) have shaped clinical practice. In this article, we investigated the perceived effects of EHR use on clinical workflow and meaningful use (MU) performance metrics. Materials and Methods Semistructured interviews were conducted with 20 (n = 20) physicians at two urban emergency departments. Interview questions focused on time spent on EHR use, changes in clinical practices with EHR use, and the effect of MU performance metrics on clinical workflow. Qualitative coding using grounded theory and descriptive analyses were performed to provide descriptive insights. Results Physicians reported that EHRs improved their clinical workflow, especially on MU-related activities including door-to-doctor time and admit decision time. EHR use also affected physicians work efficiency, quality of care provided, and overall patient safety. Conclusion Physicians' perception of EHRs is likely to influence their practices. With negative perceptions of EHR usability problems, positive aspects of EHR use, including the influence on MU performance metrics, may be overridden.
Longitudinal changes in patient-reported symptoms and physical function during taxane-based chemotherapy in breast cancer patients.
Monfort, Scott M. , Pan, Xueliang , Patrick, Robyn , Singaravelu, Janani, Mrózek, Ewa, Ramaswamy, Bhuvaneswari , Reinbolt, Raquel E. , Naughton, Michelle J. , Loprinzi, Charles L. , Chaudhari, Ajit M.W. , Layman, Rachel M. , Wesolowski, Robert , Shapiro, Charles L. , Lustberg, Maryam B.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 10098-10098

10.1200/jco.2016.34.15_suppl.10098 Get It

Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.
Somaiah, Neeta , Block, Matthew S. , Tu, Khanh, Hwu, Patrick , Jones, Robin L. , Gnjatic, Sacha , Lu, Hailing , Meulen, Jan ter , Hsu, Frank J., Gnjatic, Sacha , Jones, Robin L , Kim, Joseph W. , Shapiro, Geoffrey I. , Eder, Joseph P. , Pollack, Seth M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3093-3093

10.1200/jco.2016.34.15_suppl.3093 Get It

Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Plummer, Elizabeth Ruth, Cook, Natalie , Melear, Jason M., Redfern, Charles H., Chung, Ki Y. , Haddad, Tufia C. , Goddemeier, Thomas, Arkenau, Hendrik‐Tobias , Spira, Alexander I. , Shapiro, Geoffrey I. , Ramalingam, Suresh S. , Wesolowski, Robert , Falk, Martin H., Dean, Emma

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e21048-e21048

10.1200/jco.2018.36.15_suppl.e21048 Get It

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519

10.1200/jco.2018.36.15_suppl.5519 Get It